Evidence & regulatory context
- Mechanism
- Selective cyclooxygenase-2 inhibitor (propionic acid NSAID). Direct interaction, disease efficacy true; selectivity noted as selective. First approval 1987; now predominantly a veterinary NSAID.
- Target
- CHEMBL230 (Cyclooxygenase-2 / PTGS2)
- Injury models
- TBI
- Reported indication
- Not recorded
- First approval
- 1987
- Development stage
- Not recorded
- ChEMBL record
- CHEMBL1316 ↗
- ChEMBL max phase
- 4 / 4 (development scale, not regulatory approval)
- Synonyms
- Carprofen; Rimadyl; Carprofene; Carprofeno; NSC-297935; Ro-20-5720-000
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseTBIUnspecifiedSabraMaleafter TBI
Model: traumatic brain injury
Carprofen reduced lesion size and inflammation, improved functional outcome over 90 days and induced cell proliferation and gliogenesis after TBI.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
